Residency · Residency · Radiation Oncology

Oropharyngeal Cancer: HPV-Positive Disease and De-escalation

Overview

HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) has emerged as a distinct clinical entity characterized by a significantly better prognosis compared to HPV-negative disease. In North America and Western Europe, HPV-positive OPSCC now accounts for 70-80% of oropharyngeal cancers. Standard treatment with concurrent chemoradiation achieves a three-year overall survival (OS) exceeding 80%, which has motivated efforts to de-escalate therapy in order to reduce long-term treatment-related toxicity. De-escalation strategies under investigation include reducing the radiation dose, substituting less toxic systemic agents, and omitting chemotherapy or radiation in selected patients. However, no de-escalated regimen has yet been established as the standard of care.

HPV Biology and Epidemiology

The majority of HPV-positive OPSCC cases are caused by HPV-16, which accounts for over 90% of cases, while HPV-18 is responsible for most of the remainder. The viral oncoproteins E6 and E7 play critical roles in carcinogenesis by inactivating the tumor suppressor proteins p53 and Rb, respectively. Clinically, p16 immunohistochemistry serves as a surrogate marker for HPV status, with positivity defined as more than 70% nuclear and cytoplasmic staining. The incidence of HPV-positive OPSCC is rising, particularly among younger patients aged 40 to 60 years, predominantly males who are often non-smokers. The most common tumor subsites are the tonsil and the base of the tongue.

AJCC 8th Edition Staging (HPV-Positive)

The AJCC 8th edition introduced a separate staging system for p16-positive OPSCC to reflect its better prognosis. The T-staging remains the same as for HPV-negative disease. Clinical N-staging is categorized as cN0 (no regional lymph node metastasis), cN1 (ipsilateral lymph nodes ≤6 cm), cN2 (contralateral or bilateral lymph nodes ≤6 cm), and cN3 (lymph nodes >6 cm). Pathologic N-staging is defined as pN0 (no nodes), pN1 (four or fewer nodes), and pN2 (more than four nodes). Most patients fall into stage I or II, even when nodal disease is extensive. Notably, there is no stage IV category for non-metastatic p16-positive OPSCC in this staging system.

Standard Treatment

The current standard of care for HPV-positive OPSCC is concurrent chemoradiation, typically consisting of 70 Gy delivered in 35 fractions combined with cisplatin at 100 mg/m² every three weeks for three cycles. Primary surgery, often performed via transoral robotic surgery (TORS), followed by adjuvant radiation therapy with or without chemotherapy, is an alternative approach for selected patients. The choice of treatment depends on tumor extent, nodal involvement, anticipated functional outcomes, and institutional expertise.

De-Escalation Trials

Substituting Cetuximab for Cisplatin

One hypothesis in de-escalation research has been that cetuximab, an anti-EGFR antibody, might be less toxic than cisplatin and could be substituted without compromising efficacy. However, this has not been supported by clinical trial data.

RTOG 1016

This phase III trial compared radiation therapy combined with cisplatin versus radiation combined with cetuximab in HPV-positive OPSCC. The results demonstrated that the cetuximab arm was inferior, with a 5-year overall survival of 77.9% compared to 84.6% in the cisplatin arm. Cetuximab failed to meet the non-inferiority criteria, confirming that cisplatin remains the standard concurrent agent.

De-ESCALaTE HPV

Similarly, the De-ESCALaTE HPV phase III trial compared radiation plus cisplatin to radiation plus cetuximab in low-risk HPV-positive OPSCC patients. Cisplatin was superior, with a 2-year overall survival of 97.5% versus 89.4% for cetuximab. This trial reinforced that cetuximab should not replace cisplatin in this setting.

Reduced Radiation Dose

NRG HN002

This phase II trial evaluated two arms: 60 Gy radiation with concurrent cisplatin versus 60 Gy radiation alone in HPV-positive, non-smoking patients with T1-2 N1-2 OPSCC. The arm receiving 60 Gy plus cisplatin met the primary endpoint of a 2-year progression-free survival (PFS) greater than 85%, whereas the 60 Gy alone arm did not. These findings suggest that radiation dose reduction to 60 Gy may be feasible when combined with cisplatin but not as monotherapy.

ECOG-ACRIN E1308

In this phase II trial, patients received induction chemotherapy followed by reduced-dose radiation (54 Gy) plus cetuximab if they achieved a complete response (CR) to induction. Those with less than CR received standard-dose radiation (69.3 Gy) plus cetuximab. The reduced-dose group demonstrated a 2-year PFS of 80% and overall survival of 94%, along with better swallowing function. However, as a single-arm phase II study, these results require validation in phase III trials.

Surgery-Based De-Escalation

ECOG-ACRIN 3311

This phase II trial investigated transoral robotic surgery followed by risk-adapted adjuvant therapy. Patients classified as low-risk—those with negative surgical margins, two or fewer involved lymph nodes, and no extracapsular extension (ECE)—were observed without adjuvant radiation. Intermediate-risk patients received reduced-dose radiation (50 Gy), while high-risk patients with positive margins or ECE received standard radiation (60 Gy) plus cisplatin. The observation arm showed excellent locoregional control, supporting risk-adapted de-escalation in the postoperative setting.

Immunotherapy-Based De-Escalation

Several ongoing trials are exploring the substitution of immunotherapy for chemotherapy or using immunotherapy to enable radiation dose reduction. For example, KEYNOTE-412 compared pembrolizumab plus chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma, including HPV-positive cases, but did not meet its primary endpoint of improved event-free survival. The ongoing NRG HN005 trial is comparing standard chemoradiation to reduced-dose radiation combined with nivolumab for HPV-positive OPSCC.

Radiation Technique for OPSCC

Target Volumes

Radiation planning involves defining several target volumes. The gross tumor volume of the primary tumor (GTV-primary) includes all visible or palpable tumor identified on CT, MRI, and clinical examination. The gross tumor volume of nodal disease (GTV-nodal) encompasses all pathologic lymph nodes. The clinical target volume at high risk (CTV-high risk) includes the GTV plus a 5-10 mm margin to account for microscopic extension, as well as involved nodal levels. The intermediate-risk clinical target volume (CTV-intermediate risk) covers adjacent at-risk nodal levels, including both ipsilateral and contralateral neck regions, as bilateral treatment is typical for most oropharyngeal primaries. The low-risk clinical target volume (CTV-low risk) encompasses elective nodal levels, usually bilateral levels II-IV; level IB is included if the primary tumor extends into the oral cavity, and retropharyngeal nodes are targeted if there is posterior pharyngeal wall involvement.

Dose Prescriptions (Standard, Non-De-Escalated)

The standard radiation dose prescription delivers 70 Gy in 35 fractions to the GTV plus margin, often using a simultaneous integrated boost (SIB) to the high-risk CTV. The intermediate-risk CTV receives 63 Gy in 35 fractions, and the elective CTV receives 56 Gy in 35 fractions, or equivalent doses in sequential plans.

Key Organs at Risk (OARs)

Critical organs at risk include the parotid glands, where the mean dose should be kept below 26 Gy to at least one gland, preferably the contralateral side, to preserve salivary function. The pharyngeal constrictor muscles should receive a mean dose under 50 Gy to reduce the risk of dysphagia. The supraglottic larynx should be limited to a mean dose of 40-50 Gy. The spinal cord maximum dose should not exceed 45-50 Gy, and the mandible’s maximum dose should be kept below 70 Gy to minimize the risk of osteoradionecrosis.

<image>A comparison of AJCC 7th edition versus 8th edition staging for HPV-positive oropharyngeal cancer. A patient example with T2N2b disease (bilateral involved nodes) is staged as stage IVA in the 7th edition but downstaged to stage I in the 8th edition. Side-by-side staging tables show the dramatic stage migration, with corresponding survival curves demonstrating that 8th edition staging better stratifies prognosis.</image>

<image>A forest plot summarizing the key de-escalation trials for HPV-positive oropharyngeal cancer. Trials listed include RTOG 1016, De-ESCALaTE, NRG HN002 (both arms), E1308, and ECOG 3311 risk groups. For each trial, the experimental intervention, hazard ratio or 2-year PFS, and conclusion (positive/negative/inconclusive) are shown. Color coding distinguishes trials that support de-escalation (green), those that do not (red), and ongoing/inconclusive results (yellow).</image>

Key Clinical Pearls

Cisplatin remains the standard systemic agent for concurrent chemoradiation in HPV-positive OPSCC, as demonstrated definitively by the RTOG 1016 and De-ESCALaTE trials, which showed that cetuximab is inferior and should not replace cisplatin outside of clinical trials. While de-escalation is a promising concept aimed at reducing treatment toxicity, it has not yet produced a standard-of-care alternative; therefore, patients should be treated with standard regimens unless enrolled in a clinical trial. Smoking history remains an important prognostic factor even in HPV-positive patients; those with a smoking history exceeding 10 pack-years have worse outcomes and may be less suitable candidates for de-escalation. It is also important to recognize that p16 positivity is not perfectly specific for HPV-driven disease; in non-oropharyngeal sites such as the oral cavity, larynx, or hypopharynx, p16 positivity does not confer the same favorable prognosis and should not alter management without confirmatory HPV testing, such as in situ hybridization. Finally, because patients with HPV-positive OPSCC are likely to survive their cancer, functional outcomes including swallowing, speech, and xerostomia are as important as survival, and treatment decisions should explicitly consider long-term quality of life.

References

• Gillison ML et al. "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016)." J Clin Oncol. 2019;37(2):163-174.
• Mehanna H et al. "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV)." Lancet. 2019;393(10166):51-60.
• Marur S et al. "E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx." J Clin Oncol. 2017;35(5):490-497.
• Ferris RL et al. "Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3311)." J Clin Oncol. 2022;40(2):138-149.
• Yom SS et al. "Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)." J Clin Oncol. 2021;39(9):956-965.

Read this lecture as Markdown